

**Amendments to the claims:**

The following listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (canceled)
2. (Currently amended) The vaccine composition as claimed in claim + 17, wherein said polysaccharide is the capsular polysaccharide of *Haemophilus influenzae* type b or Polynbosylribitol Phosphate.
3. (Currently amended) The vaccine composition as claimed in claim + 17, wherein said polysaccharide is a pneumococcal polysaccharide.
4. (Currently amended) The vaccine composition as claimed in claim + 17, wherein said polysaccharide is a meningococcal polysaccharide
5. (Currently amended) The vaccine composition as claimed in claim + 17, wherein the said carrier protein is tetanus toxoid.
6. (Currently amended) The vaccine composition as claimed in claim + 17, wherein said carrier protein is diphtheria toxoid.
7. (Currently amended) The vaccine composition as claimed in claim + 17, wherein the quantity of trehalose is between 3 and 12% by mass.
8. (Currently amended) The vaccine composition as claimed in claim + 17, wherein the quantity of trehalose is about 5%.
9. (Currently amended) A method of preserving the immunogenicity over time of a liquid vaccine composition comprising at least one antigen consisting of a polysaccharide bound to a carrier protein, wherein the method comprises adding-combining in a liquid (a) trehalose to the vaccine composition and (b) the antigen to form a liquid vaccine composition, and maintaining-storing the vaccine composition in a-the liquid state.

10. (Previously presented) The method as claimed in claim 9, wherein the quantity of trehalose to be added is between 3 and 12% by mass.
11. (Previously presented) The vaccine composition as claimed in claim 7, wherein said polysaccharide is the capsular polysaccharide of *Haemophilus influenzae* type b or Polynbosylribitol Phosphate.
12. (Previously presented) The vaccine composition as claimed in claim 7, wherein said polysaccharide is a pneumococcal polysaccharide.
13. (Previously presented) The vaccine composition as claimed in claim 7, wherein said polysaccharide is a meningococcal polysaccharide
14. (Previously presented) The vaccine composition as claimed in claim 7, wherein the said carrier protein is tetanus toxoid.
15. (Previously presented) The vaccine composition as claimed in claim 7, wherein said carrier protein is diphtheria toxoid.
16. (Previously presented) The method of claim 10, wherein the quantity of trehalose is about 5% by mass.
17. (New) A liquid vaccine composition prepared by a process comprising:
  - (a) combining in a liquid (a) trehalose with (b) at least one antigen consisting of a polysaccharide bound to a carrier protein to form a liquid vaccine composition, and
  - (b) storing the liquid vaccine composition in the liquid state.